LIVN:NGS-LivaNova PLC

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 73.08

Change

+0.38 (+0.52)%

Market Cap

USD 2.11B

Volume

0.41M

Analyst Target

USD 88.14
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

LivaNova PLC is a medical technology company formed by the merger of Sorin S.p.A, engaged in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-1.58 (-1.16%)

USD 51.34B
ALGN Align Technology Inc

-10.23 (-3.25%)

USD 23.70B
BRKR Bruker Corporation

-1.83 (-2.09%)

USD 12.93B
PODD Insulet Corporation

-1.28 (-0.73%)

USD 11.49B
SWAV Shockwave Medical Inc

-0.60 (-0.18%)

USD 10.25B
MASI Masimo Corporation

+0.19 (+0.14%)

USD 7.14B
AXNX Axonics Modulation Technologie..

-0.27 (-0.40%)

USD 3.45B
IRTC iRhythm Technologies Inc

-3.64 (-3.22%)

USD 3.36B
QDEL Quidel Corporation

-0.72 (-1.71%)

USD 3.14B
IART Integra LifeSciences Holdings

-0.74 (-2.26%)

USD 2.64B

ETFs Containing LIVN

W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.08 (-2.40%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.08 (-2.40%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.08 (-2.40%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.15 (-2.40%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.10% 29% F 15% F
Dividend Return N/A N/A N/A N/A F
Total Return -20.10% 29% F 15% F
Trailing 12 Months  
Capital Gain -28.76% 45% F 29% F
Dividend Return N/A N/A N/A N/A F
Total Return -28.76% 45% F 29% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain 21.01% 63% D 78% C+
Dividend Return 21.01% 63% D 77% C+
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 35.96% 67% D+ 38% F
Risk Adjusted Return 58.42% 76% C+ 78% C+
Market Capitalization 2.11B 93% A 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 77.40 33% 14%
Price/Book Ratio 2.38 62% 44%
Price / Cash Flow Ratio 0.00 78% 85%
Price/Free Cash Flow Ratio 0.00 78% 84%
Management Effectiveness  
Return on Equity -12.77% 71% 34%
Return on Invested Capital N/A N/A N/A
Return on Assets 1.33% 78% 56%
Debt to Equity Ratio 9.30% 69% 78%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector